Loading...

Nachrichtenliste

New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

2022-11-25


New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

Abbvie announced that the European Commission has approved a new indication for Skyrizi, its novel anti-inflammatory IL-23 inhibitor: Skyrizi 600mg intravenous induction and 360mg subcutaneous maintenance therapy were used to treat adults with moderate to severe active Crohn's disease who were under-responsive, unresponsive, or intolerant to conventional or biological therapies. It is worth mentioning that Skyrizi is the first specific IL-23 inhibitor approved for the treatment of CD in the European Union and the United States.

Wir möchten Cookies verwenden, um Ihre Nutzung dieser Website besser zu verstehen und Ihre Erfahrung bei zukünftigen Besuchen der Website zu verbessern. Sie können diese Einstellung in Ihren Browsereinstellungen ändern. Weitere Informationen zur Verwendung von Cookies finden Sie in unserer Datenschutzrichtlinie.